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Abstract 
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple 
sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability 
in the subset of MS patients with EDSS 4–7. Recent responder subgroup analyses in the Phase 3 
ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-
reported 12-item Multiple Sclerosis Walking Scale in the 43% of patients classified as responders to 
PR-fampridine, corresponding to a standardised response mean of 1.68. Use of PR-fampridine in 
clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of 
European MS experts met in June 2017 to discuss their experience with using PR-fampridine, 
including their views on the patient population for treatment, assessment of treatment response, re-
testing and re-treatment, and stopping criteria. This article summarises the experts’ opinions on how 
PR-fampridine can be used in real-world clinical practice to optimise the benefits to people with MS 
with impaired walking ability. 
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Introduction 
Multiple sclerosis (MS) causes a wide variety of neurological deficits, but ambulatory impairment is 
the most common form of disability. Within 15 years of disease onset, 50% of people with MS will 
require assistance with walking and 80% will experience gait problems due to muscle weakness, 
spasticity, fatigue and balance impairment [Souza 2010]. In a large US cohort, 15% of MS patients 
reported needing ambulatory aid in the first year of disease, increasing to 40% after 10 years; after 
45 years of disease, 76% of patients required ambulatory aid and 52% needed at least bilateral 
assistance [Kist et al. 2013]. Impaired mobility is associated with reductions in quality of life, 
activities of daily living and productivity, and patients with MS rank maintaining mobility as one of 
their highest priorities [Sutliff 2010; Heesen 2008].  
Prolonged-release (PR) fampridine (known as sustained/modified-release fampridine in some 
countries and extended-release dalfampridine in the US) is the only approved medication for MS 
that improves walking. It received full approval from the European Medicines Agency (EMA) in May 
2017, following approval in 2011 conditional on further studies being conducted. PR-fampridine is 
indicated for the improvement of walking in adult MS patients with walking disability (Expanded 
Disability Status Scale [EDSS] score 4–7) [Fampyra SmPC 2017]. Fampridine is thought to block 
voltage-gated potassium channels, restoring signal conduction in demyelinated nerve fibres [Dunn 
2011]. 
This article describes new responder subgroup analyses of the ENHANCE study, which clarify 
treatment effects in patients who respond to PR-fampridine. It also reports on the clinical 
experience of 14 MS experts from 10 European countries (Belgium, France, Germany, Italy, 
Netherlands, Norway, Portugal, Slovenia, Spain and the UK), which was discussed at a meeting held 
in June 2017. Topics discussed include real-world experience with PR-fampridine, expert views on 
the patient population for PR-fampridine, assessment of treatment response, re-testing and re-
treatment, and stopping criteria, based on early EU clinical experience. 
 
New analyses of the fampridine study program – understanding the real patient impact 
Two Phase 3 multicentre, randomised, double-blind, placebo-controlled trials showed that PR-
fampridine produced clinically meaningful improvement in walking ability in a subset of MS patients 
[Goodman 2009, 2010]. In the first trial, the proportion of patients with any type of MS who 
responded (consistent improvement on Timed 25-Foot Walk [T25FW] over 14 weeks) was 
significantly higher in the PR-fampridine group than in the placebo group (35% vs. 8%; p<0.0001). 
T25FW responders showed greater improvement on the 12-item Multiple Sclerosis Walking Scale 
(MSWS-12) than did non-responders (p=0.0002) [Goodman 2009]. The T25FW is considered the 
most well-characterised objective, specific assessment of walking disability, and is moderately to 
strongly correlated with self-reported walking disability on the MSWS-12 [Kieseier 2012]. The second 
trial confirmed these findings, with 43% of the PR-fampridine group being T25FW responders 
compared with 9% of the placebo group (p<0.0001) [Goodman 2010]. Long-term extensions of the 
two trials showed that improvements in walking speed were lost after PR-fampridine was 
discontinued in the parent trial, but returned by the 2-week assessment after re-initiation. Although 
walking speed decreased over time, PR-fampridine responders sustained an improved walking speed 
compared with non-responders for up to 5 years [Goodman 2015]. 
The MOBILE trial explored the effect of PR-fampridine on patients’ self-assessed walking ability and 
dynamic/static balance, assessed using the MSWS-12, the Timed Up and Go (TUG) test and the Berg 
Balance Scale (BBS) [Hupperts 2016]. PR-fampridine therapy resulted in greater median 
improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 
24 weeks, as well as greater improvements in the 29-item MS Impact Scale (MSIS-29) physical 
impact subscale (PHYS) [Hupperts 2016]. A post-hoc analysis showed a mean reduction from 
baseline of 97% versus placebo in MSIS-29 PHYS among patients who achieved a clinically significant 
≥8-point mean reduction in MSWS-12 score over 24 weeks with PR-fampridine, and a reduction of 
111% in the psychological subscale of MSIS-29 [Gasperini 2016]. 
ENHANCE, the largest and longest randomised trial of PR-fampridine to date, was a Phase 3 
multicentre, randomised, double-blind, placebo controlled study to evaluate whether PR-fampridine 
provided sustained, clinically meaningful benefits compared with placebo on patient-reported 
walking ability and other functional outcome measures [Hobart 2016]. Patients aged 18–70 years 
with relapsing or progressive MS and impaired walking (EDSS 4–7) were randomised to PR-
fampridine 10 mg (n=317) or placebo (n=319) twice daily for 24 weeks. Significantly more patients in 
the PR-fampridine group than in the placebo group achieved a clinically meaningful ≥8-point mean 
improvement from baseline on the MSWS-12 over 24 weeks. Significant differences in favour of PR-
fampridine were also reported for TUG speed and improvement from baseline MSIS-29 PHYS 
[Hobart et al. 2016]. Overall tolerability of prolonged-release fampridine in the ENHANCE trial was 
consistent with previous clinical trials. 
Recent responder subgroup analyses in ENHANCE showed an improvement in MSWS-12 score of 
20.58 points among PR-fampridine MSWS-12 responders, compared with a deterioration of 2.17 
points (least square mean [LSM] difference -22.76 [95% CI -25.25, -20.26]) in non-responders and an 
improvement of 3.64 (LSM difference -16.94 [95% CI -19.21, -14.68]) in placebo-treated patients 
[Hobart et al. 2017]. The proportion of patients with clinically significant improvements (≥15%) in 
TUG speed was significantly higher in PR-fampridine responders (52.4% [95% CI, 1.47 to 3.53]) than 
in non-responders (36.6%) or the placebo group (34.7%). Improvements in MSWS-12 scores and TUG 
speeds in responders were observed as early as Week 2 and were sustained over 24 weeks. Benefits 
were also seen in responders versus non-responders/placebo for changes in MSIS-29 PHYS, BBS and 
ABILHAND scores over 24 weeks [Hobart 2017]. LSM changes from baseline were -17.4 in 
responders, -1.9 in non-responders and -5.3 with placebo for MSIS-29 PHYS; 2.6, 1.2 and 1.4, 
respectively for BBS; and 3.3, 0.3 and 0.9, respectively, for ABILHAND. The experts who met in June 
2017 considered that this responder subgroup analysis approach was justified because, in clinical 
practice, only patients who respond to PR-fampridine remain on treatment.  
New effect size analyses have been conducted with the aim of contextualising the effect sizes seen 
in the PR-fampridine responder and non-responder subgroups in ENHANCE. These examined the 
mean change in points on the MSWS-12 scale relative to the standard deviation of change and have 
specific criteria for interpretation. Standardised response mean (SRM) values were calculated for PR-
fampridine MSWS-12 responder and non-responder groups as 1.68 and 0.36, respectively, for 
MSWS-12. As many studies are powered to detect an effect size of 0.3, an effect size of 1.68 in 
responders was thought to represent an impressive result. Similar calculations were conducted for 
other outcome measures from ENHANCE, such as effect versus baseline disability and Berg Balance 
Scale at baseline, with PR-fampridine MSWS-12 responders showing strong results relative to non-
responders. 
 
Real-word experience with PR-fampridine 
PR-fampridine received full EMA approval in May 2017, following conditional approval in 2011. 
However, worldwide experience is much more extensive and, as of 30 April 2017, more than 318,565 
patients had been treated with PR-fampridine, representing more than 341,163 patient-years of 
exposure (including ~8321 patients and ~3367 patient-years from clinical trials) (Data on file, Biogen 
2017). 
Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is 
reimbursed. Healthcare systems in many European countries now reimburse PR-fampridine subject 
to certain response criteria. However, reimbursement is not currently available in the UK and several 
other countries, meaning that access to PR-fampridine treatment for people with MS remains 
variable. PR-fampridine is less well documented in real-world multicentre activities or national MS 
registries than other products, although the first publications describing multicentre observational 
studies, rather than single-centre cohorts, are beginning to appear [Fragoso 2016; Costa-Arpin 2016; 
Rodriguez-Leal 2017]. 
The experts who met in June 2017 have a broad experience of using PR-fampridine in their MS 
patients, which was assessed by questionnaires at the meeting:  The group of experts oversees a 
total of over 11000 patients, over 1400 of these under treatment with PR-fampridine.   Due to 
different local situations regarding health-care systems as well as license and reimbursement of the 
drug in the different countries the rate of fampridine treated patients differs between the experts’ 
centres, ranging from below 10% in Belgium and Italy to around 25% in Germany and Spain to about 
40% in Denmark. The majority of the PR-fampridine treated patients at the centres were classified as 
secondary progressive MS (48%), followed by relapsing remitting (35%) and primary progressive 
(17%) MS with a rather homogenous distribution over the EDSS steps 4(21%), 5(23%), 6(35%) and 
7(21%). The experts often use PR-fampridine in combination with disease-modifying therapies, as 
well as with non-pharmacological approaches such as physiotherapy and occupational therapy. Half 
of their currently treated patients have been taking PR-fampridine for 3–4 years, with another 30% 
taking it for 5 or more years. 
 
Patient population – which patients are most likely to benefit from PR-fampridine? 
PR-fampridine is currently indicated for the improvement of walking in adults with MS who have 
walking disability (EDSS 4–7). However, the experts believe that some people with MS even with 
EDSS scores below 4 may already have impaired walking [Langeskov-Christensen 2017] and other 
deficits such as visual impairment, nystagmus or ataxia, and may receive considerable benefit from 
PR-fampridine treatment. This is supported by reports on an improvement of visual acuity and visual 
evoked potential latencies in patients with optic neuropathy [Horton 2013], an amelioration of 
downbeat nystagmus [Kalla 2007, Claassen 2013] and ataxia [Schiepp 2012] under therapy with 4-
aminopyridine also in non-MS patients.  How patients walk can be as important as how far or how 
fast they can walk. Similarly, at higher EDSS levels, meaningful and impactful improvements in hand 
function may be achievable; these are less apparent as study populations do not include patients 
with major hand dysfunction. As PR-fampridine works by improving neuronal function, the experts 
suggested that it may lead to greater improvement in patients with more deficits. Even very disabled 
patients may be able to use their wheelchairs more easily and effectively. Overall, more data on the 
use of PR-fampridine in patients with EDSS scores below 4 and above 7 would be welcome, including 
information on walking impairment, fatigue, upper limb function and cognition. 
Newer tools that have a potential role in identifying patients with mobility impairment who may 
benefit from PR-fampridine treatment were discussed. For example, the Early Mobility Impairment 
Questionnaire (EMIQ) is a nine-item questionnaire designed to capture MS patients’ experience with 
mobility impairment [Ziemssen 2016]. It includes more high level motor activities than the MSWS-
12, such as items on walking in crowds and stability while walking on flat or uneven ground. Early 
experience suggests that it has the potential to be used as a screening tool to identify mobility 
impairment at an earlier stage. 
With regards to a concordant relationship and shared decision making, clear communication is 
needed when prescribing PR-fampridine, so that patients have realistic expectations. It is important 
to explain to patients that not everyone experiences an improvement; however, they will know very 
quickly whether the drug works for them or not. The experience of the experts suggests that most 
patients are very positive about trying the drug. 
 
Assessing treatment response 
The EU label for PR-fampridine has recently been updated to recommend that clinical benefit is 
evaluated on the basis of walking ability rather than walking speed as specified previously, and the 
timescale for initial evaluation is now ‘within 2–4 weeks’, rather than ‘after 2 weeks’, which had 
been recommended previously. Both MSWS-12 and T25FW are included in the label as suitable tools 
for evaluating response to allow both clinical and patient-reported assessments. 
Variations exist across Europe in terms of the documented evidence of response required by the 
various authorities for reimbursement purposes, and in some cases this drives the methods used to 
evaluate response. At the meeting, the experts agreed that the patient-reported MSWS-12 is 
currently the most commonly used measure for formal assessment of treatment response, along 
with T25FW. Some would use extra measures, such as assessment of hand function using the 9-Hole 
Peg Test or ABILHAND, if a patient has additional deficits. A recent single-centre study found that a 
combination of the T25FW and MSWS-12 offered the best sensitivity and specificity for determining 
response to both neurologists’ and patients’ classification [Rodriguez-Leal 2017]. Thresholds for 
reimbursement need to be pragmatic; each authority sets its own threshold, with an improvement 
of 30% on MSWS-12 or 20% on T25FW being commonly used. The experts noted that in many cases, 
it is obvious after 2 weeks whether a patient is responding to PR-fampridine; however, some 
patients may need to continue treatment for a further 2 weeks to be certain. 
Based on the experts’ real-world experience with PR-fampridine, there was agreement that the 
benefits of PR-fampridine to patients may be broader than just on walking speed. Several experts 
stated that patients could see improvements in terms of gait pattern, walking endurance, balance 
and fatigability. The experts noted that patients have better balance when taking PR-fampridine; 
they may not walk faster but they feel safer [Gonzalez 2016; Gonzalez-Suarez 2015, 2016; Prosperini 
2014]. The Timed 100-Meter Walk Test may be useful for assessing walking speed over a longer 
distance [Phan-Ba 2011], while a cut-off of 15% change from the first to the last minute of the 6-
Minute Walk Test (6MWT) has been suggested to identify walking-related motor fatigue [Leone 
2016], which may be affected by PR-fampridine. Some experts also reported improvements in vision 
and ataxia, although these are not included in the label indication. As the mode of action of PR-
fampridine is to improve nerve conduction, it was thought that treatment benefits were unlikely to 
be confined to walking ability alone. Indeed, PR-fampridine has been shown to improve arm 
function, fatigue and quality of life in T25FW/MSWS-12/2-minute walk test responders [Allart 2015]. 
The 9-Hole Peg Test is likely to be useful for monitoring hand function, as it is a simple, validated 
measure of upper limb function in MS and is highly correlated with a wide range of other upper limb 
tests [Feys 2017]. Improvement has also been demonstrated with PR-fampridine treatment [Savin 
2016]. In addition, PR-fampridine has been shown to significantly improve cognitive impairment in a 
single-centre study, as measured by processing speed according to the Symbol Digit Modalities Test 
[De Giglio 2017]. 
This expert group agreed that patient-reported outcomes were particularly important for a 
treatment that improves symptoms, and that predefined questionnaires and rating scales inevitably 
have their limitations in assessing overall clinical improvements. Specific goal-related outcomes such 
as the ability to walk upstairs or reach the bathroom may be of real practical significance to people 
with MS and can be measured using goal attainment scaling [Turner-Stokes 2009]. The ability to walk 
confidently with one walking aid rather than two could also be a meaningful outcome in some cases. 
Overall, as PR-fampridine is a symptomatic treatment, the experts agreed that it would seem 
reasonable to be able to continue treatment if both the physician and the patient believe that the 
drug is working, and that patients would generally be unwilling to take a drug that was not effective 
for them. This is evident in countries such as the UK, where PR-fampridine is not reimbursed and 
patients must decide whether to pay for the drug themselves. 
Based on the label recommendation, treatment should be stopped if the patient reports no benefit 
from PR-fampridine after 2–4 weeks. However, the experts noted that some patients may 
deteriorate when the drug is stopped, suggesting that they were receiving some benefit from 
treatment. The effect of stopping PR-fampridine appears to distinguish quite well between 
responders and non-responders. Furthermore, disease activity and clinical symptoms may progress, 
and the experts noted that in some cases response to fampridine may change later in the course of 
disease despite an earlier negative response (see below). 
 
Re-testing, stopping treatment and re-treating 
On the basis of their practical experience, the experts considered that asking PR-fampridine-treated 
patients every 6 months whether the drug is still working for them was good practice, as well as 
assessing them for side effects, walking ability and other outcomes. Drug holidays could be used to 
determine whether the drug still has a therapeutic benefit. If it no longer appears to be effective, the 
drug should be stopped. However, there is the possibility of re-starting treatment if the clinical 
situation changes. EDSS >7 is generally used as a stopping criterion for PR-fampridine treatment in 
current clinical practice, based on the label, but different criteria may be needed for other domains 
such as hand function. 
A recent long-term extension of a randomised controlled trial of PR-fampridine found that 80% of 
patients who showed greater than 10% improvement in T25FW and 6MWT in the original study 
maintained their response over 2 years in the extension. However, 40% of patients who did not 
achieve this level of response during short-term treatment (6 weeks) showed greater than 10% 
improvements after 2 years [Filli 2017]. The authors speculate that responsiveness to PR-fampridine 
may change over time, as MS is a dynamic disease and appearance of new demyelinated lesions may 
result in clinical deterioration amenable to improvement; enhanced drug efficacy over time may also 
be the result of training effects made possible by the improved neurological state induced by PR-
fampridine [Filli 2017]. 
In the experts’ experience, some people with MS (possibly as many as a third) who initially do not 
respond to fampridine may respond to a second attempt at treatment. A re-trial of PR-fampridine 
between 6 and 12 months after an initial failure is a reasonable approach, especially if the disease 
course has changed and if the person with MS is willing to try the treatment again. Some patients 
may not wish to try a drug again if it did not work for them on the first attempt, but an increase in 
symptoms or disability may prompt a second attempt. 
 
Conclusions 
PR-fampridine has been shown to improve walking ability in a subset of MS patients with impaired 
mobility, and recent responder subgroup analyses of the ENHANCE study have shown very large 
effect sizes in terms of an average increase in MSWS-12 score of 20.58 points among PR-fampridine 
MSWS-12 responders. Similarly, more than 52% of PR-fampridine MSWS-12 responders showed 
meaningful improvements in TUG speed. 
Early real-world experience suggests that the benefits of PR-fampridine may extend beyond those on 
walking ability, based on its mode of action which involves restoring neuronal function.  
This article has provided expert opinions on how PR-fampridine can be used in real-world clinical 
practice to optimise the benefits to people with MS with impaired walking ability. 
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